<DOC>
	<DOC>NCT02391116</DOC>
	<brief_summary>To assess the potential efficacy (in terms of objective response) of single agent copanlisib in patients with relapsed or refractory Diffuse large B-cell lymphoma (DLBCL) and assess the relationship between efficacy and a potentially predictive biomarker</brief_summary>
	<brief_title>Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<criteria>Diagnosis of Diffuse large Bcell lymphoma (DLBCL) (de novo or DLBCL transformed from follicular lymphoma on the basis of a tissue biopsy). Received at least one prior therapy for aggressive NonHodgkin's Lymphoma (NHL) (DLBCL) Patients must have measurable disease. ECOG (Eastern Cooperative Oncology Group) performance status (PS) ≤ 2 Left ventricular ejection fraction (LVEF) ≥ the lower limit of normal (LLN) for the Institution (as per local standard of care) as measured by echocardiogram (ECHO) or Multiple gated acquisition (MUGA) scan Adequate bone marrow, liver and renal function. Any of the following as the only site(s) of disease: palpable lymph nodes not visible on imaging studies, skin lesions, or bone marrow involvement only Active CTCAE (Common Terminology Criteria for Adverse Events) Grade 3/4 infection Known history of human immunodeficiency virus (HIV) infection Current central nervous system (CNS) involvement by lymphoma Unstable angina (angina symptoms at rest), newonset angina (begun within the last 3 months). Myocardial infarction within the past 6 months before start of study treatment Type I or II diabetes mellitus with HbA1c &gt; 8.5% or fasting plasma glucose &gt; 160 mg/dL at Screening. New York Heart Association (NYHA) class III or IV heart disease Concurrent participation in other clinical studies. Patients who previously received therapy with copanlisib or other PI3K inhibitors are not eligible for enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>